Carvedilol
Carvedilol. Combined β₁/β₂ + α₁ antagonist. α₁ blockade produces vasodilation offsetting β-blocker-induced afterload rise — advantageous in… Oral half-life 6.4 h.
Combined β₁/β₂ + α₁ antagonist. α₁ blockade produces vasodilation offsetting β-blocker-induced afterload rise — advantageous in HFrEF. Evidence-base-first-line HF β-blocker (COPERNICUS trial 35% mortality reduction).
PK: EVERY STORED NUMBER CAME FROM A BIOEQUIVALENCE ABSTRACT REPORTING ONLY Cmax AND AUC — AND TWO OF THEM ARE ITS SAMPLING TIMES. That abstract schedule opens "at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2", and the record stored F 0.25 and ka 1.5. Its only bioavailability figure is a RELATIVE one, "The relative bioavailability of the test formulation to reference formulation was 100.1%". A real intravenous-and-oral crossover supplies all four verbatim: "For the 50 mg capsule Cmax was 66 micrograms.l-1, tmax 1.2 h, t1/2 6.4 h. The t1/2 after i.v. administration was 2.4 h, CL 589 ml/min and VZ 132 l. The absolute bioavailability was 24% (50 mg capsule)." The volume is intravenous-derived, so the new pairing is legitimate. FLIP-FLOP IS EXPLICIT IN THIS LITERATURE — the oral 6.4 h against an intravenous 2.4 h is absorption-dependent — so the oral value is carried on the oral route and the intravenous one recorded here. The racemate question is answered: both cited assays were ACHIRAL, so no cross-enantiomer mean was taken. Its effect-compartment value is the best-sourced number in its group and is untouched.
Pharmacokinetics
- Oral — t½ 6.4 h · F 24% · Vd 132 L
Sources: PMID:32608144, PMID:15655528, PMID:3428345, PMID:15306222